YMAB241220P30000
- 0.00
- 0.000.00%
Y-mAbs Therapeutics Newsroom
Oppenheimer Initiates Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $23
Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock
Oppenheimer Initiates Coverage On Y-mAbs Therapeutics With Outperform Rating, Announces Price Target of $23
Y-mAbs Therapeutics Analyst Ratings
H.C. Wainwright Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $22
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Institutional Investors Lost 13% Last Week but Have Benefitted From Longer-term Gains
JonesTrading Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $23
Truist Financial Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $21
Truist Financial Remains a Buy on Y-Mabs Therapeutics (YMAB)
Y-Mabs Therapeutics: Promising Pipeline Developments and Strong Revenue Projections Justify Buy Rating
Morgan Stanley Maintains Y-mAbs Therapeutics(YMAB.US) With Sell Rating, Maintains Target Price $11
Y-Mabs Therapeutics Faces Uncertain Growth Amid Declining Danyelza Sales and Market Challenges
Y-mAbs Therapeutics, Inc. (YMAB) Q3 2024 Earnings Call Transcript Summary
Y-mAbs Therapeutics, Inc. (YMAB) Q3 2024 Earnings Call Transcript
Y-mAbs Therapeutics | 10-Q: Q3 2024 Earnings Report
Y-mAbs Therapeutics | 8-K: Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
Y-mAbs Therapeutics GAAP EPS of -$0.16 Beats by $0.01, Revenue of $18.46M Misses by $4.8M
Y-mAbs Therapeutics: Cash and Cash Equivalents Anticipated to Continue to Support Ops as Currently Planned Into 2027 >YMAB
Express News | Y-mAbs Therapeutics - Reiterates Full Year 2024 Guidance
Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q3 Revenue $18.5M